AstraZeneca's MedImmune, Mirati Therapeutics Partner on Immuno-oncology Combination in Lung Cancer
August 05, 2015 at 04:27 AM EDT
AstraZeneca (NYSE: AZN) today announced that MedImmune, its global biologics research and development arm, has entered into an exclusive ...